The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of ART-123 in combination with FOLFOX + bevacizumab for patients with metastatic colorectal cancer.
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb Corporation; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Afshin Gabayan
Employment - Beverly Hills Cancer Center & Clinical Research Advisors LLC
Leadership - Medical Director a Beverly Hills Cancer Center & Clinical Research Advisors LLC
Stock and Other Ownership Interests - erly Hills Cancer Center & Clinical Research Advisors LLC
Honoraria - Janssen; Pfizer
Research Funding - rincipal Investigator on clinical trials at Beverly Hills Cancer Center & Clinical Research Advisors LLC
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yujiro Nishizawa
No Relationships to Disclose
 
Taito Esaki
Honoraria - Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Lilly; MSD; Ono Pharmaceutical; Roche Diagnostics Solutions; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Asahi Kasei (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Nihonkayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Yusuke Suwa
No Relationships to Disclose
 
Patrick Cobb
Stock and Other Ownership Interests - Abbott Laboratories; Alnylam; crispr therapeutics; Intuitive Surgical; Johnson & Johnson/Janssen; United Health Group
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Altor BioScience (Inst); Aptose Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BeiGene (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Galera Therapeutics (Inst); Genentech/Roche (Inst); Hengenix (Inst); ImmunityBio (Inst); Incyte (Inst); Innocare (Inst); Innovent Biologics (Inst); Ipsen (Inst); Isofol Medical (Inst); Lilly (Inst); MEI Pharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); Tolmar (Inst); Veloxis (Inst); Viracta Therapeutics (Inst); XBiotech (Inst); Xiamen Enchang Group (Inst)
 
Naoki Nagata
No Relationships to Disclose
 
Yoshiyuki Yamamoto
No Relationships to Disclose
 
Hironaga Satake
Honoraria - Asahi KASEI; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Guardant Health; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Asahi Kasei (Inst); MSD (Inst)
 
Mitsuru Yokota
No Relationships to Disclose
 
Kunihiro Fushiki
No Relationships to Disclose
 
Takeshi Kajiwara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasushi Tsuji
Honoraria - Daiichi-Sankyo Co. Ltd.; Kyowa Kirin; MSD Co. Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical
 
Victor Priego
Research Funding - Afimmune; AstraZeneca; Protagonist Therapeutics; Veloxis
 
Ryo Sugiyama
Employment - Asahi Kasei
 
Kentaro Yamazaki
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Taiho Pharmaceutical (Inst)
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Ichinosuke Hyodo
Consulting or Advisory Role - Asahi Kasei; Chugai Pharma; Daiichi Sankyo Co.,Ltd.; Eisai; Ono Pharmaceutical; Taiho Pharmaceutical